Analyst downgrades AstraZeneca stock due to vaccine side effect concerns

The odds of experiencing a fatal blood clot following inoculation with AstraZeneca's COVID-19 vaccine are less than one in a million, but that was enough to spook Argus Research.

women in a lab carrying out a medical experiment

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Shares of AstraZeneca (NASDAQ: AZN) are under pressure again following an analyst downgrade. Concerns about the pharmaceutical company's coronavirus vaccine led Argus Research to lower its rating on the stock from buy to hold on Monday morning.

Last Wednesday, the European Medicines Agency (EMA) said unusual blood clots with low blood platelets should be listed as a very rare side effect of AstraZeneca's COVID-19 vaccine, recently given the trade name Vaxzevria. The risk of death from COVID-19 is many orders of magnitude greater, but delays to Vaxzevria's European roll-out had already damaged public opinion regarding it. Across the EU and the U.K., around 34 million people have been vaccinated as of April 4, 2021. Over that period, 222 blood clots were reported to the EMA's side-effect hotline. The vast majority of those were non-fatal.

Vaccine hesitancy in the EU and U.S. is already a problem, and the slightest hint of a dangerous side effect will make it more difficult, if not impossible, for AstraZeneca to earn significant profits from Vaxzevra. That said since the company had already committed to selling the vaccine at cost during the pandemic, and on a permanent not-for-profit basis to low- and middle-income countries, AstraZeneca shareholders don't have much to worry about in terms of lost profits from Vaxzevra over the long run anyway.

The roll-out of this particular COVID-19 vaccine has been a disappointment, but investors need to remember that AstraZeneca isn't a vaccine company. It's an oncology-focused drugmaker and a highly successful one with rapidly rising profits.

Unless cancer patients suddenly begin caring about who markets their therapies, COVID-19 vaccine hesitancy isn't going to appreciably impact AstraZeneca's earnings. The company's product lineup sports a handful of recently approved treatments that could push the company's bottom line and its stock price steadily higher for years to come.  

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A man in a business suit peers through binoculars as two businesswomen stand beside him looking straight ahead at the camera.
International Stock News

The US stock market is doing something witnessed only 3 times in 154 years — and history makes clear what happens next

If things seem too good to be true on Wall Street, they just might be.

Read more »

A fortune teller looks into a crystal ball in an office surrounded by business people.
International Stock News

My top 3 Nvidia predictions for February 26

The tech giant will soon offer us more details about the launch of a very important product.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
International Stock News

Will Donald Trump's new sweeping tariffs cause a US stock market crash? History couldn't be any clearer

Trump's "America First" ethos may come at a big cost to the stock market.

Read more »

Confused African-American girls in casual clothing standing outdoors and comparing information on smartphones.
International Stock News

Should you forget Nvidia shares and buy this artificial intelligence (AI) stock instead?

Nvidia remains a solid stock, but is this AI company a better buy for the long term?

Read more »

a business exec making a grab for money
International Stock News

3 reasons I'm still loading up on Nvidia shares

Nvidia's clients haven't changed their spending decisions following DeepSeek's breakthrough.

Read more »

Smiling woman driving a car.
International Stock News

Who owns Tesla?

Aside from Elon Musk, who else has skin in the game?

Read more »

A little boy surrounded by green grass and trees looks up at the sky, waiting for rain or sunshine.
International Stock News

Prediction: Nvidia stock is going to soar after February 26

Nvidia stock has started 2025 badly, but it may be able to regain its mojo later this month.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
International Stock News

Mark Zuckerberg just delivered incredible news for Nvidia stock investors

What did Meta Platforms CEO Mark Zuckerberg say and what does it mean for AI stocks like Nvidia?

Read more »